Category: therapy
-
Growth Hormone Therapy Market Set to Double by 2032 – Here’s Why
•
The growth hormone treatment market passes rapidly, driven by progress in biotechnology, increased awareness of hormonal health, and high demand for treatments that generally enhance luxury. Industry expectations expect a steady growth, as medicine giants are largely investing in research and development. With the intensification of competition, companies are racing…
-
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
•
Sangamo Therapeutics shares decline as Pfizer terminates hemophilia gene therapy agreement on monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for the treatment of severe-to-moderate hemophilia A that it co-developed and licensed. Pfizer (NYSE: PFE). Pfizer has…
-
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England
•
Article content Nyxoah announces the commercial launch of its innovative treatment Genio® in EnglandThe first patients to have the Genio device implanted At UCLH, London Article content Mont Saint Guibert, Belgium – December 13, 2024, 8:05 AM CET / 2:05 AM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or…
-
Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Oct 04, 2024 • 6 minute…
-
Why gene therapy for sickle cell is slow to catch on with patients By Reuters
•
Written by Dina Beasley LOS ANGELES (Reuters) – Student Zoe Davis, 20, was just weeks into her first year of school when she returned to the hospital with severe sickle cell pain earlier this month. She does what she can to prevent the bouts of paralysis in her arms, legs…
-
Why gene therapy for sickle cell is slow to catch on with patients By Reuters
•
Written by Dina Beasley LOS ANGELES (Reuters) – Student Zoe Davis, 20, was just weeks into her first year of school when she returned to the hospital with severe sickle cell pain earlier this month. She does what she can to prevent the bouts of paralysis in her arms, legs…
-
Creative arts therapy: Medics draw, dance and write their way through burnout
•
Doctors and nurses rarely learn in school how to tell a family that a loved one will not survive. Yet healthcare workers face the enormous burden of tragedy, illness, and death in a highly stressful environment as a constant routine part of their jobs. Long before the COVID-19 pandemic, research…
-
Vertex sues US over fertility support program for Casgevy gene editing therapy By Reuters
•
(Reuters) – Vertex Pharmaceuticals Inc. sued the U.S. Department of Health and Human Services on Monday seeking a court declaration that its fertility support program for patients prescribed its gene-editing treatment Kasgevi does not violate federal anti-kickback laws. Casgevy is approved to treat two genetic disorders — sickle cell disease…
-
Vertex sues US over fertility support program for Casgevy gene editing therapy By Reuters
•
(Reuters) – Vertex Pharmaceuticals Inc. sued the U.S. Department of Health and Human Services on Monday seeking a court declaration that its fertility support program for patients prescribed its gene-editing treatment Kasgevi does not violate federal anti-kickback laws. Casgevy is approved to treat two genetic disorders — sickle cell disease…
-
Ionis stock gains on data for HAE therapy (NASDAQ:IONS)
•
Evening pictures Ionis Pharmaceuticals (Nasdaq: ions(Amazon) announced Friday that its investigational treatment dondalorsen has achieved positive results in two late-stage trials for hereditary angioedema (HAE), a rare genetic disorder characterized by body swelling. Citing data from the phase III studies OASIS-HAE and OASISplus, the company Dundalorsen, an RNA-targeted treatment, reduced…